

<b>1. Adı Soyadı</b>	Hazire Oya ALPAR
<b>2. Doğum Tarihi</b>	-
<b>3. Unvanı</b>	Prof. Dr.

<b>4. Öğrenim Durumu</b>	<b>Derece</b>	<b>Alan</b>	<b>Üniversite</b>	<b>Yıl</b>
	Lisans	Eczacılık	Ankara Üniversitesi	1966
	Y. Lisans	Eczacılık	Londra Üniversitesi	1968
	Doktora	Farmasötik Teknoloji (Pharmaceutics)	Londra Üniversitesi	1971

<b>5. Akademik Unvanlar</b>	<b>Unvan</b>	<b>Üniversitesi</b>	<b>Tarihi</b>
	Dr. Öğretim Üyesi		
	Doçentlik		<b>1976</b>
	Profesörlük	Hacettepe Üniversitesi UCL, Eczacılık Fakültesi Emeritus Profesör, UCL Eczacılık Fakültesi İstanbul Kemerburgaz Üniversitesi	1980 1999 2009 2012

<b>6. Yönetilen Yüksek Lisans ve Doktora Tezleri</b>	<b>Tez Adı</b>	<b>Danışman</b>	<b>Yılı</b>
<b>6. 2. Yönetilen Doktora Tezleri</b>	Formulation and evaluation of particulate systems for targeted delivery of vaccines, Sally Galal Abd El-Haleem. UCL Eczacılık Fakültesi, Londra Üniversitesi		2010
	Polysaccharide based nanocarriers for the delivery of vaccines, Stefan Salomon. UCL Eczacılık Fakültesi, Londra Üniversitesi		2007
	Development of non-invasive vaccine carriers, Burcu Sayın. UCL Eczacılık Fakültesi, Londra Üniversitesi		2007
	Development of Polymeric Gene Delivery Systems Aiming at Potential DNA Vaccines, Xiong Wei Li. UCL Eczacılık Fakültesi, Londra Üniversitesi		2005
	Diphtheria toxoid loaded poly-(ε-caprolactone) nanoparticles as mucosal vaccine delivery systems, Jsvinder Singh. UCL Eczacılık Fakültesi, Londra Üniversitesi		2004
	Polymer-modified liposomes for drug and vaccine delivery, Claire Martin. UCL Eczacılık Fakültesi, Londra Üniversitesi		2003
	Novel formulations for antigen delivery using biodegradable polymers: new approaches for the use of new and established adjuvants, Sima Hayavi. UCL Eczacılık Fakültesi, Londra Üniversitesi		2002
	Novel bioadhesive formulations for mucosal and parenteral delivery of vaccines, Satyanarayana Somavarapu. Aston Üniversitesi		2001

	Freeze-drying: a rational approach to process development and product formulation using model polymeric proteins and drug microcarrier systems, Kevin R. Ward. Aston Üniversitesi		1997
	Oral uptake and distribution of microspheres, James Edward Eyles. Aston Üniversitesi		1995
	Particulate carriers as immunological adjuvants, Antonio J.L. Almeida. Aston Üniversitesi		1993
	Influence of microbial antigen formulation and delivery route on the immune response, Joanne C.Bowen. Aston Üniversitesi		1990
	Development of a novel in vitro system for nasal drug delivery development, Jonathan D. Turner. Aston Üniversitesi		2000
	Allerjik aşıların uzun tesirli preparat haline geliştirilmesi yöntemleri üzerinde çalışmalar, Uğur Soyal. Hacettepe Üniversitesi		1974

		<b>Makale / Tebliğ Başlığı</b>	<b>Dergi / Konferans Adı</b>	<b>Yeri</b>	<b>Yayın Tarihi</b>	<b>Sayfa</b>	<b>Eş Yazar</b>
<b>7. Yayınlar</b>	<b>7.1. Uluslararası hakemli dergilerde yayınlanan makaleler</b>	Modified chitosan-based nanoadjuvants enhance immunogenicity of protein antigens after mucosal vaccination. Sinani, G., Sessevmez, M, Gök, MK, Özgümüş, S, Alpar, HO, Cevher, E.	Int J Pharm.	-	2019	118592	5
		Nasal vaccination with poly ( $\beta$ -amino ester)-poly(d,l-lactide-co-glycolide) hybrid nanoparticles. Sinani, G., Sessevmez, M., Gök, M.K., Özgümüş, S., Okyar, A., Alpar, H.O., Cevher, E.	Int J Pharm.		2017	529(1-2), pp. 1-14.	6
		Development of chitosan-pullulan composite nanoparticles for nasal delivery of vaccines: in vivo studies. Cevher, E., Salomon, S.K., Somavarapu, S, Brocchini, S, Alpar, H.O.	J Microencapsul.		2015	32(8), pp.769-83.	5
		Development of chitosan-pullulan composite nanoparticles for nasal delivery of vaccines: optimisation and cellular studies. Cevher, E., Salomon, S.K., Makrakis, A., Li, X.W., Brocchini, S, Alpar, HO.	J Microencapsul.		2015	32(8):755-68.	6

		Influence of Suspension Stabilisers on the Delivery of Protein-Loaded Porous Poly (DL-Lactide-co-Glycolide) (PLGA) Microparticles via Pressurised Metered Dose Inhaler (pMDI) Cocks, E., Somavarapu, S., Alpar, O., Greenleaf, D.	Pharmaceutical Research		2014	31(8),pp. 2000-2009	4
		Inhalable DNase I microparticles engineered with biologically active excipients, Osman, R., Al Jamal, K.T., Kan, P.-L., (...), EL-Shamy, A.-E., Alpar, O.	Pulmonary Pharmacology and Therapeutics		2013	26 (6), pp. 700-709	7
		Bluetongue virus infection induces aberrant mitosis in mammalian cells, Shaw, A.E., Brüning-Richardson, A., Morrison, E.E., (...), Mertens, P.P.C., Monaghan, P.	Virology Journal		2013	10, 319	5
		Spray dried inhalable ciprofloxacin powder with improved aerosolisation and antimicrobial activity, Osman, R., Kan, P.L., Awad, G., (...), El-Shamy, A.-E., Alpar, O.	International Journal of Pharmaceutics		2013	449 (1-2), pp. 44-58	7
		Protection of IFNAR (-/-) Mice against Bluetongue Virus Serotype 8, by Heterologous (DNA/rMVA) and Homologous (rMVA/rMVA) Vaccination, Expressing Outer-Capsid Protein VP2 Jabbar, T.K., Calvo-Pinilla, E., Mateos, F., (...), Mertens, P.P.C., Castillo-Olivares	J., PLoS ONE 8		2013	(4), e60574	7
		Biolistic transfection of human embryonic kidney (HEK) 293 cells, Li, X., Uchida, M., Alpar, H.O., Mertens, P.	Methods in Molecular Biology		2013	940, pp. 119-132	4
		Enhanced properties of discrete pulmonary deoxyribonuclease I (DNaseI) loaded PLGA nanoparticles during encapsulation and activity determination, Osman,	International Journal of Pharmaceutics		2011	408 (1-2), pp. 257-265	5

		R., Kan, P.L., Awad, G., (...), El-Shamy, A.-E., Alpar, O.					
		Biomechanical Characterization of a Micro/Macroporous Polycaprolactone Tissue Integrating Vascular Graft, Wang, Y., Lam, J., Zhang, B., (...), Jones, A.S., Coombes, A.G.A.	Cardiovascular Engineering and Technology		2010	1 (3), pp. 202-215	5
		Surface modified polymeric nanoparticles for immunisation against equine strangles, Florindo, H.F., Pandit, S., Gonçalves, L.M.D., Alpar, H.O., Almeida, A.J.	International Journal of Pharmaceutics		2010	390 (1), pp. 25-31	5
		TMC-MCC (N-trimethyl chitosan-mono-N-carboxymethyl chitosan) nanocomplexes for mucosal delivery of vaccines, Sayin, B., Somavarapu, S., Li, X.W., (...), Şenel, S., Alpar, O.H.	European Journal of Pharmaceutical Sciences		2009	38 (4), pp. 362-369	5
		Simultaneously Manufactured Nano-In-Micro (SIMANIM) particles for dry-powder modified-release delivery of antibodies, Kaye, R.S., Purewal, T.S., Alpar, H.O.	Journal of Pharmaceutical Sciences		2009	98 (11), pp. 4055-4068	3
		Antibody and cytokine-associated immune responses to S. equi antigens entrapped in PLA nanospheres, Florindo, H.F., Pandit, S., Gonçalves, L.M.D., (...), Alpar, O., Almeida, A.J.,	Biomaterials		2009	30 (28), pp. 5161-5169	5
		An investigation into the combination of low frequency ultrasound and liposomes on skin permeability, Dahlan, A., Alpar, H.O., Murdan, S.,	International Journal of Pharmaceutics		2009	379 (1-2), pp. 139-142	3
		Transfection by particle bombardment: Delivery of plasmid DNA into mammalian cells using gene gun, Uchida, M., Li, X.W., Mertens, P., Alpar,	Biochimica et Biophysica Acta - General Subjects		2009	1790 (8), pp. 754-764	4

		H.O.,					
		Delivery of bioactive macromolecules from microporous polymer matrices: Release and activity profiles of lysozyme, collagenase and catalase, Wang, Y., Chang, H.-I., Li, X., Alpar, O., Coombes, A.G.A.	European Journal of Pharmaceutical Sciences		2009	37 (3-4), pp. 387-394	5
		Development and testing of particulate formulations for the nasal delivery of antibodies, Kaye, R.S., Purewal, T.S., Alpar, O.H.,	Journal of Controlled Release		2009	135 (2), pp. 127-135	3
		Preparation of polyethyleneimine incorporated poly(D,L-lactide-co-glycolide) nanoparticles by spontaneous emulsion diffusion method for small interfering RNA delivery, Kat3as, H., Cevher, E., Alpar, H.O.,	International Journal of Pharmaceutics		2009	369 (1-2), pp. 144-154	3
		Transcutaneous immunisation assisted by low-frequency ultrasound, Dahlan, A., Alpar, H.O., Stickings, P., Sesardic, D., Murdan, S.	International Journal of Pharmaceutics		2009	368 (1-2), pp. 123-128	5
		New approach on the development of a mucosal vaccine against strangles: Systemic and mucosal immune responses in a mouse model, Florindo, H.F., Pandit, S., Gonçalves, L.M.D., Alpar, H.O., Almeida, A.J. ,	Vaccine		2009	27 (8), pp. 1230-1241	5
		23. The enhancement of the immune response against <i>S. equi</i> antigens through the intranasal administration of poly- $\epsilon$ -caprolactone-based, Florindo, H.F., Pandit, S., Lacerda, L., (...), Alpar, H.O., Almeida, A.J.,	Biomaterials		2009	30 (5), pp. 879-891	5

		Effect of preparative variables on small interfering RNA loaded Poly(D,L-lactide-co-glycolide)-chitosan submicron particles prepared by emulsification diffusion method, Katas, H., Chen, S., Osamuyimen, A.A., Cevher, E., Alpar, H.O.,	Journal of Microencapsulation		2008	25 (8), pp. 541-548	5
		Non-viral dried powders for respiratory gene delivery prepared by cationic and chitosan loaded liposomes, Colonna, C., Conti, B., Genta, I., Alpar, O.H.,	International Journal of Pharmaceutics		2008	364 (1), pp. 108-118	4
		Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery, Sayin, B., Somavarapu, S., Li, X.W., (...), Alpar, H.O., Şenel, S.	International Journal of Pharmaceutics		2008	363 (1-2), pp. 139-148	5
		Streptococcus equi antigens adsorbed onto surface modified poly-ε-caprolactone microspheres induce humoral and cellular specific immune responses, Florindo, H.F., Pandit, S., Gonçalves, L.M.D., Alpar, H.O., Almeida, A.J.,	Vaccine		2008	26 (33), pp. 4168-4177	5
		Development and initial evaluation of a real-time RT-PCR assay to detect bluetongue virus genome segment 1, Shaw, A.E., Monaghan, P., Alpar, H.O., (...), Mellor, P.S., Mertens, P.P.C.,	Journal of Virological Methods		2007	145 (2), pp. 115-126	5
		Characterization of nucleic acid molecule/liposome complexes and rheological effects on pluronic/alginate matrices, Grassi, G., Farra, R., Noro, E., (...), Rehimers, B., Grassi, M. ,	Journal of Drug Delivery Science and Technology		2007	17 (5), pp. 325-331	5

		Enhancement of immune response of HBsAg loaded poly (L-lactic acid) microspheres against Hepatitis B through incorporation of alum and chitosan, Pandit, S., Cevher, E., Zariwala, M.G., Somavarapu, S., Alpar, H.O.	Journal of Microencapsulation		2007	24 (6), pp. 539-552	5
		Development and characterisation of chitosan nanoparticles for siRNA delivery, Katas, H., Alpar, H.O.	Journal of Controlled Release		2006	115 (2), pp. 216-225	2
		The preparation of liposomes using compressed carbon dioxide: Strategies, important considerations and comparison with conventional techniques, Bridson, R.H., Santos, R.C.D., Al-Duri, B., (...), Robertson, J., Alpar, H.O.	Journal of Pharmacy and Pharmacology		2006	58 (6), pp. 775-785	5
		Protection against bubonic and pneumonic plague with a single dose microencapsulated sub-unit vaccine, Elvin, S.J., Eyles, J.E., Howard, K.A., (...), Alpar, H.O., Williamson, E.D.	Vaccine		2006	24 (20), pp. 4433-4439	5
		Modulating the adjuvanticity of alum by co-administration of muramyl di-peptide (MDP) or Quil-A, Moschos, S.A., Bramwell, V.W., Somavarapu, S., Alpar, H.O.	Vaccine			24 (8), pp. 1081-1086	4
		Diphtheria toxoid loaded poly-(ε-caprolactone) nanoparticles as mucosal vaccine delivery systems, Singh, J., Pandit, S., Bramwell, V.W., Alpar, H.O.,	Methods		2006	38 (2), pp. 96-105	4
		H. Oya Alpar; "New frontiers in vaccines for emerging pathogens"	Advance Drug Delivery Reviews		2005	57 pages 1243-1246	

		Cholesterol-bile salt vesicles as potential delivery vehicles for drug and vaccine delivery, Martin, C., Thongborisute, J., Takeuchi, H., (...), Kawashima, Y., Alpar, H.O.	International Journal of Pharmaceutics		2005	298 (2), pp. 339-343	5
		Positively charged rifampicin-loaded microspheres for lung delivery, Pandit, S., Martin, C., Alpar, H.O.	Journal of Drug Delivery Science and Technology		2005	15 (4), pp. 281-287	3
		Mucosal delivery of diphtheria toxoid using polymer-coated-bioadhesive liposomes as vaccine carriers, Martin, C., Somavarapu, S., Alpar, H.O.	Journal of Drug Delivery Science and Technology			15 (4), pp. 301-306	3
		Immobilisation of vaccines onto micro-crystals for enhanced thermal stability, Murdan, S., Somavarapu, S., Ross, A.C., Alpar, H.O., Parker, M.C.	International Journal of Pharmaceutics		2005	296 (1-2), pp. 117-121	5
		Mechanisms of inactivation of HSV-2 during storage in frozen and lyophilized forms Hansen, R.K., Zhai, S., Skepper, J.N., (...), Alpar, H.O., Slater, N.K.H.	Biotechnology Progress		2005	21 (3), pp. 911-917	5
		Comparative immunomodulatory properties of a chitosan-MDP adjuvant combination following intranasal or intramuscular immunization, Moschos, S.A., Bramwell, V.W., Somavarapu, S., Alpar, H.O.	Vaccine		2005	23 (16), pp. 1923-1930	4
		Adjuvant synergy: The effects of nasal coadministration of adjuvants, Moschos, S.A., Bramwell, V.W., Somavarapu, S., Alpar, H.O.	Immunology and Cell Biology		2004	82 (6), pp. 628-637	4
		Increased resistance of DNA lipoplexes to protein binding in vitro by surface-modification with a multivalent hydrophilic polymer, Papanicolaou, I., Briggs, S., Alpar, H.O.,	Journal of Drug Targeting		2004	12 (8), pp. 541-547	3



		Immunisation against plague by transcutaneous and intradermal application of subunit antigens, Eyles, J.E., Elvin, S.J., Westwood, A., (...), Somavarapu, S., Williamson, E.D.	Vaccine		2004	22 (31-32), pp. 4365-4373	5
		Formulation of a microparticle carrier for oral polyplex-based DNA vaccines, K.A., Li, X.W., Somavarapu, S., (...), Seymour, L.W., Alpar, H.O.	Biochimica et Biophysica Acta - General Subjects		2004	1674 (2), pp. 149-157	5
		Potential use of nanoparticles for transcutaneous vaccine delivery: Effect of particle size and charge, Kohli, A.K., Alpar, H.O.	International Journal of Pharmaceutics		2004	275 (1-2), pp. 13-17	2
		Strategies for Vaccine Delivery, Alpar, H.O.	Journal of Drug Targeting		2003	Vol. 11, No. 8-10, pages 459-461	1
		Oral plasmid DNA delivery systems for genetic immunization, Somavarapu, S., Bramwell, V.W., Alpar, H.O.	Journal of Drug Targeting		2003	11 (8-10), pp. 547-553	3
		52. Adjuvant action of melittin following intranasal immunisation with tetanus and diphtheria toxoids, Bramwell, V.W., Somavarapu, S., Outschoorn, I., Alpar, H.O.	Journal of Drug Targeting		2003	11 (8-10), pp. 525-530	4
		Immunological aspects of polymer microsphere vaccine delivery systems, Eyles, J.E., Carpenter, Z.C., Alpar, H.O., Williamson, E.D.	Journal of Drug Targeting		2003	11 (8-10), pp. 509-514	4
		An information rich biomedical polymer library, Pedone, E., Li, X., Koseva, N., Alpar, O., Brocchini, S.	Journal of Materials Chemistry		2003	13 (11), pp. 2825-2837	5
		Sustained expression in mammalian cells with DNA complexed with chitosan nanoparticles, Li, X.W., Lee, D.K.L., Chan, A.S.C., Alpar, H.O.	Biochimica et Biophysica Acta - Gene Structure and Expression		2003	1630 (1), pp. 7-18	4

		Encapsulation of plasmid DNA in PLGA-stearylamine microspheres: A comparison of solvent evaporation and spray-drying methods, Atuah, K.N., Walter, E., Merkle, H.P., Alpar, H.O.	Journal of Microencapsulation		2003	20 (3), pp. 387-399	4
		Stimulation of spleen cells in vitro by nanospheric particles containing antigen, Eyles, J.E., Bramwell, V.W., Singh, J., Williamson, E.D., Alpar, H.O.	Journal of Controlled Release		2003	86 (1), pp. 25-32	5
		Protection against plague following immunisation with microencapsulated V antigen is reduced by co-encapsulation with IFN- $\gamma$ or IL-4, but not IL-6, Griffin, K.F., Eyles, J.E., Spiers, I.D., Alpar, H.O., Williamson, E.D.	Vaccine		2002	20 (31-32), pp. 3650-3657	5
		Liposome/DNA complexes coated with biodegradable PLA improve immune responses to plasmid encoding hepatitis B surface antigen, Bramwell, V.W., Eyles, J.E., Somavarapu, S., Alpar, H.O.	Immunology		2002	106 (3), pp. 412-418	4
		The development of polyplex-based DNA vaccines Howard, K.A., Alpar, H.O.	Journal of Drug Targeting		2002	10 (2), pp. 143-151	2
		Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice, Flick-Smith, H.C., Eyles, J.E., Hebdon, R., (...), Baillie, L.W.J., Williamson, E.D.	Infection and Immunity		2002	70 (4), pp. 2022-2028	4
		Microsphere translocation and immunopotential in systemic tissues following intranasal administration, Eyles, J.E., Bramwell, V.W., Williamson, E.D., Alpar, H.O.	Vaccine		2001	19 (32), pp. 4732-4742	4

		Tissue distribution of radioactivity following intranasal administration of radioactive microspheres, Eyles, J.E., Spiers, I.D., Williamson, E.D., Alpar, H.O.	Journal of Pharmacy and Pharmacology		2001	53 (5), pp. 601-607	4
		Effects of formulation vehicle and microsphere composition on the onset of immune response, Hayavi, S., Somavarapu, S., Baillie, L., Williamson, E.D., Alpar, H.O.	Journal of Pharmacy and Pharmacology		2000	52 (9 SUPPL.), pp. 31	5
		Single nasal and oral administration of microencapsulated antigen leads to a high and sustainable immune response, Ward, K.R., Somavarapu, S., Williamson, E.D., Alpar, H.O.	Journal of Pharmacy and Pharmacology		2000	52 (9 SUPPL.), pp. 19	4
		Absorption of polylactic acid particles in Caco-2 cell model: Impact of different formulation strategies Authors of Document Tran, C.D.H., Bampfield, C., Somavarapu, S., Alpar, H.O.	Journal of Pharmacy and Pharmacology		2000	52 (9 SUPPL.), pp. 26	4
		Stearylamine and polyethylenimine improve encapsulation of plasmid DNA into microspheres Atuah, K.N., Seymour, L.W., Alpar, H.O.	Journal of Pharmacy and Pharmacology		2000	52 (9 SUPPL.), pp. 87	3
		Effect of differential time point addition of sucrose on liposome characteristics during freezing and freeze drying, Martin, C., Bramwell, V.W., Alpar, H.O.	Journal of Pharmacy and Pharmacology		2000	52 (9 SUPPL.), pp. 29	3
		Reduction of in-vitro cytotoxicity of liposome/DNA complexes by incorporation of $\alpha$ -tocopherol, Bramwell, V.W., Bampfield, C., Tran, C.D.H., Alpar, H.O.	Journal of Pharmacy and Pharmacology		2000	52 (9 SUPPL.), pp. 30	4

		Biodegradable microparticles with different release profiles: Effect on the immune response after a single administration via intranasal and intramuscular routes, Spiers, I.D., Eyles, J.E., Baillie, L.W.J., Williamson, E.D., Alpar, H.O.	Journal of Pharmacy and Pharmacology		2000	52 (10), pp. 1195-1201	5
		Protection studies following bronchopulmonary and intramuscular immunisation with Yersinia pestis F1 and V subunit vaccines coencapsulated in biodegradable microspheres: A comparison of efficacy Eyles, J.E., Williamson, E.D., Spiers, I.D., Alpar, H.O.	Vaccine		2000	18 (28), pp. 3266-3271	4
		Physicochemical and biological characterisation of an antisense oligonucleotide targeted against the bcl-2 mRNA complexed with cationic-hydrophilic copolymers, Read, M.L., Dash, P.R., Clark, A., (...), Ulbrich, K., Seymour, L.W.	European Journal of Pharmaceutical Sciences		2000	10 (3), pp. 169-177	5
		Generation of protective immune responses to plague by mucosal administration of microsphere coencapsulated recombinant subunits, Eyles, J.E., Williamson, E.D., Spiers, I.D., (...), Jones, S.M., Alpar, H.O.	Journal of Controlled Release		2000	63 (1-2), pp. 191-200	5
		Novel bioadhesive liposomes for use in vaccine delivery, Bramwell, V., Somavarapu, S., Alpar, H.O.	Journal of Pharmacy and Pharmacology		1999	51 (SUPPL.), pp. 315	3
		Mucosal administration of block copolymer stabilised nanospheres containing recombinant vaccines, Eyles, J.E., Alpar, H.O., Williamson,	Journal of Pharmacy and Pharmacology		1999	51 (SUPPL.), pp. 316	3

	E.D.					
	The immune responses following nasal and intra muscular administration of tetanus toxoid adsorbed on PLA lamellae, Somavarapu, S., Coombes, A.G.A., Alpar, H.O.	Source of the Document Journal of Pharmacy and Pharmacology		1999	51 (SUPPL.), pp. 124	3
	N-Trimethyl chitosan chloride acts to enhance immunogenicity of mucosally applied subunit vaccines, Alpar, H.O., Eyles, J.E., Somavarapu, S., (...), Thanou, M., Williamson, E.D.	Journal of Pharmacy and Pharmacology		1999	51 (SUPPL.), pp. 182	5
	Immunological responses to nasal delivery of free and encapsulated tetanus toxoid: Studies on the effect of vehicle volume, Eyles, J.E., Williamson, E.D., Alpar, H.O.	International Journal of Pharmaceutics		1999	189 (1), pp. 75-79	3
	Protection of the enzyme L-asparaginase during lyophilisation - A molecular modelling approach to predict required level of lyoprotectant, Ward, K.R., Adams, G.D.J., Alpar, H.O., Irwin, W.J.	International Journal of Pharmaceutics		1999	187 (2), pp. 153-162	4
	Studies on the co-encapsulation, release and integrity of two subunit antigens: rV and rF1 from Yersinia pestis, Spiers, I.D., Alpar, H.O., Eyles, J.E., (...), Miller, J., Williamson, E.D.	Journal of Pharmacy and Pharmacology		1999	51 (9), pp. 991-997	5
	Antimicrobial properties of liposomal polymyxin B, McAllister, S.M., Alpar, H.O., Brown, M.R.W.	Journal of Antimicrobial Chemotherapy		1999	43 (2), pp. 203-210	3
	Development of a novel nasal chamber designed to mimic conditions found in the human nasal cavity, Turner, J.D., Alpar, H.O., Randall, L., Simpkin, G., Irwin,	Proceedings of the Controlled Release Society		1999	(26), pp. 337-338	5

		W.J.					
		Analysis of local and systemic immunological responses after intra-tracheal, intra-nasal and intra-muscular administration of microsphere co-encapsulated <i>Yersinia pestis</i> sub-unit vaccines, Eyles, J.E., Spiers, I.D., Williamson, E.D., Alpar, H.O.	Vaccine		1998	16 (20), pp. 2000-2009	4
		84. Chitosan microspheres for nasal delivery of model antigen bovine serum albumin, Somavarapu, S., He, P., Ozsoy, Y., Alpar, H.O.	Journal of Pharmacy and Pharmacology		1998	50 (SUPPL. 9), pp. 166	4
		Biodegradable nanoparticles stabilized with block co-polymer surfactants and encapsulating <i>Yersinia pestis</i> rF1 antigen for oral vaccination against plague, Alpar, H.O., Pepper, T.C., Williamson, E.D.	Journal of Pharmacy and Pharmacology		1998	50 (SUPPL. 9), pp. 101	3
		Biodegradable nanoparticles in nasal vaccine delivery: Effect of particle size and loading, Somavarapu, S., Alpar, H.O., Song, C.Y.S.	Proceedings of the Controlled Release Society		1998	(25), pp. 645-646	3
		Intra nasal administration of poly-lactic acid microsphere co-encapsulated <i>Yersinia pestis</i> subunits confers protection from pneumonic plague in the mouse, Eyles, J.E., Sharp, G.J.E., Williamson, E.D., Spiers, I.D., Alpar, H.O.	Vaccine		1998	16 (7), pp. 698-707	5
		PDLLA microspheres containing steroids: Spray-drying, o/w and w/o/w emulsifications as preparation methods, Giunchedi, P., Alpar, H.O., Conte, U.	Journal of Microencapsulation		1998	15 (2), pp. 185-195	3

		Immune responses to V antigen of <i>Yersinia pestis</i> co-encapsulated with IFN- $\gamma$ : Effect of dose and formulation, Griffin, K.F., Conway, B.R., Alpar, H.O., Williamson, E.D.	Vaccine		1998	16 (5), pp. 517-521	4
		Immune responses following pulmonary delivery of PLLA microsphere co-encapsulated <i>Yersinia pestis</i> antigens, Eyles, J.E., Alpar, H.O., Spiers, I.D., Williamson, E.D.	Proceedings of the Controlled Release Society		1998	(25), pp. 641-642	4
		Two intra-nasal administrations of PLLA co-encapsulated <i>Y. pestis</i> sub-units confers protection from plague, Alpar, H.O., Eyles, J.E., Spiers, I.D., Williamson, E.D.	Proceedings of the Controlled Release Society		1998	(25), pp. 639-640	4
		Interaction of polymyxin B (PXB) with liposomal bilayers, McAllister, S.M., Alpar, H.O.	Proceedings of the Controlled Release Society		1998	(25), pp. 413-414	2
		A comparative study on the immune responses to antigens in PLA and PHB microspheres Conway, B.R., Eyles, J.E., Alpar, H.O.	Journal of Controlled Release		1997	49 (1), pp. 1-9	3
		Oral delivery and fate of poly(lactic acid) microsphere-encapsulated interferon in rats, Eyles, J.E., Alpar, H.O., Conway, B.R., Keswick, M.	Journal of Pharmacy and Pharmacology		1997	49 (7), pp. 669-674	4
		Single and coencapsulation of interferon- $\gamma$ in biodegradable PLA microspheres for optimization of multicomponent vaccine delivery vehicles, Conway, B.R., Alpar, H.O.	Delivery: Journal of Delivery and Targeting of Therapeutic Agents		1997	4 (2), pp. 75-80	2
		Studies on the optimisation of microsphere formulation for <i>Yersinia pestis</i> antigens for oral delivery: Humoral and cellular responses, Eyles, J.E., Alpar, H.O., Sharp, G.J.E., Williamson, E.D.	Proceedings of the Controlled Release Society		1997	(24), pp. 251-252	4

		Immunological responses following oral and intra-muscular administration of PLA microspheres manufactured using surfactants with adjuvant properties, Alpar, H.O., Akbuga, J., Eyles, J.E., Williamson, E.D.	Proceedings of the Controlled Release Society		1997	(24), pp. 785-786	4
		Local and systemic immune response to a microencapsulated sub-unit vaccine for plague, Williamson, E.D., Sharp, G.J.E., Eley, S.M., (...), Titball, R.W., Alpar, H.O.	Vaccine		1996	14 (17-18), pp. 1613-1619	5
		The immune responses and protective efficacy of the skinner herpes simplex virus vaccine administered by oral and nasal routes in liposomes, Bowen, J.C., Alpar, H.O., Phillipotts, R., Brown, M.R.W.	Journal of Liposome Research		1995	5 (1), pp. 193-214	4
		Expression and stability of herpes simplex virus antigens in Salmonella typhimurium Authors of DocumentBowen, J.C., Reddy, R.M., Alpar, H.O., Brown, M.R.W., Rouse, B.T.	Advances in Experimental Medicine and Biology		1995	371 (B), pp. 1543-1546	6
		The transfer of polystyrene microspheres from the gastrointestinal tract to the circulation after oral administration in the rat, Eyles, J., Alpar, H.O., Field, W.N., Lewis, D.A., Keswick, M.	Journal of Pharmacy and Pharmacology		1995	47 (7), pp. 561-565	5
		The effects of formulation of PLA microspheres on immune responses: An in vivo study, Alpar, H.O., Conway, B.R., Bowen, J.C.	Proceedings of the Controlled Release Society		1995	(22), pp. 564-565	3
		Immune responses to mucosally administered tetanus toxoid in biodegradable PLA microspheres Alpar, H.O., Almeida, A.J., Brown, M.R.W., Williamson, E.D.	Proceedings of the Controlled Release Society		1994	(21), pp. 867-868	4



		P281 microsphere adjuvanticity: Influence of polymer, dose and size on the humoral response to microencapsulated tetanus toxoid, Almeida, A.J., Alpar, H.O.	European Journal of Pharmaceutical Sciences		1994	2 (1-2), pp. 189	2
		Studies on the optimisation of loading and release kinetics of interferon-gamma from polylactide microspheres, Conway, B.R., Alpar, H.O., Lewis, D.A.	Proceedings of the Controlled Release Society		1994	(21), pp. 284-285	3
		Liposomal polymyxin B: Characterisation and pulmonary delivery Authors of DocumentMcAllister, S.M., Alpar, H.O., Brown, M.R.W.	Proceedings of the Controlled Release Society		1994	(21), pp. 336-337	3
		Identification of some of the physico-chemical characteristics of microspheres which influence the induction of the immune response following mucosal delivery Alpar, H.O., Almeida, A.J.	European Journal of Pharmaceutics and Biopharmaceutics		1994	40 (4), pp. 198-202	2
		Microsphere absorption by the nasal mucosa of the rat, Alpar, H.O., Almeida, A.J., Brown, M.R.W.	Journal of Drug Targeting		1994	2 (2), pp. 147-149	3
		Preparation, properties and the effects of free and liposomal tobramycin on siderophore production by Pseudomonas aeruginosa, Poyner, E.A., Alpar, H.O., Brown, M.R.W.	Journal of Antimicrobial Chemotherapy		1994	34 (1), pp. 43-52	3
		Immune response to nasal delivery of antigenically intact tetanus toxoid associated with Poly(L-lactic acid) microspheres in rats, rabbits and guinea-pigs, Almeida, A.J., Alpar, H.O., Brown, M.R.W.	Journal of Pharmacy and Pharmacology		1993	45 (3), pp. 198-203	3
		Liposomal (MLV) polymyxin B: Drug association and drug-lipid interactions, Lawrence, S.M., Alpar, H.O., Brown, M.R.W.	Proceedings of the Controlled Release Society		1993	(20), pp. 486-487	3

		Formulation studies on particulate carriers as immunological adjuvants, Almeida, A.J., Alpar, H.O., Brown, M.R.W.	Proceedings of the Controlled Release Society		1993	(20), pp. 390-391	3
		Effectiveness of liposomes as adjuvants of orally and nasally administered tetanus toxoid, Alpar, H.O., Bowen, J.C., Brown, M.R.W.	International Journal of Pharmaceutics		1992	88 (1-3), pp. 335-344	3
		Poly(lactic acid) microspheres as immunological adjuvants for orally delivered cholera toxin B subunit, Almeida, A.J., Alpar, H.O., Williamson, D., Brown, M.R.W.	Biochemical Society Transactions		1992	20 (4), pp. 316S	4
		The use of albumin microspheres in the treatment of carrageenan-induced inflammation in the rat Lewis, D.A., Field, W.N., Hayes, K., Alpar, H.O.	Journal of Pharmacy and Pharmacology		1992	44 (3), pp. 271-274	4
		Mucosal delivery of herpes simplex virus vaccine, Bowen, J.C., Alpar, H.O., Phillipotts, R., Brown, M.R.W.	Research in Virology		1992	143 (4), pp. 269-278	4
		Production and characterization of monoclonal antibodies to outer membrane proteins of Pseudomonas aeruginosa grown in iron-depleted media, Smith, A.W., Wilton, J., Clark, S.A., (...), Melling, J., Brown, M.R.W.	Journal of General Microbiology		1991	137 (2), pp. 227-236	5
		In vitro evaluation of antibacterial activities of liposomal, tobramycin against Pseudomonas aeruginosa, Alpar, H.O., Rovamo, L., Devi, K., (...), Collier, P.J., Brown, M.R.W.	Journal of Pharmacy and Pharmacology, Supplement		1991	43, pp. 61	5
		Preliminary studies on infection by attenuated Salmonella in guinea pig and on expression on herpes simplex virus, Bowen, J.C., Alpar, O., Phillipotts, R., Roberts, I.S., Brown, M.R.W.	Research in Microbiology		1990	141 (7-8), pp. 873-877	5

		Non-parenteral delivery of tetanus toxoid vaccine using liposomes, Bowen, J.C., Alpar, H.O., Brown, M.R.W.	Journal of Pharmacy and Pharmacology, Supplement		1990	42, pp. 147P	3
		Oral delivery of viral protein antigens using lipid carrier systems, Bowen, J.C., Alpar, H.O., Brown, M.R.W.	Journal of Pharmacy and Pharmacology, Supplement		1990	42, pp. 146P	3
		Estimation by FACS of the delivery of liposome encapsulated macromolecules into myeloid cells, Alpar, H.O., Bason, A.M., Hickman, J.A., Richards, F.M., Field, W.N.	International Journal of Pharmaceutics		1990	62 (2-3), pp. 133-141	5
		A possible use of orally administered microspheres in the treatment of inflammation, Alpar, H.O., Field, W.N., Hayes, K., Lewis, D.A	Journal of Pharmacy and Pharmacology, Supplement		1989	41, pp. 50P	4
		Effects of formulation and transmucosal delivery sites on the immune response of PEV-01 vaccine, Alpar, H.O., Bowen, J.C., Brown, M.R.W.	Journal of Pharmacy and Pharmacology, Supplement		1989	41, pp. 137P	3
		The transport of microspheres from the gastro-intestinal tract to inflammatory air pouches in the rat, Alpar, H.O., Field, W.N., Hyde, R., Lewis, D.A.	Journal of Pharmacy and Pharmacology		1989	41 (3), pp. 194-196	4
		Drug-delivery by ion-exchange. Part IV: Coated resinate complexes of ester pro-drugs of propranolol, Irwin, W.J., Belaid, K.A., Alpar, H.O.	Drug Development and Industrial Pharmacy		1988	14 (10), pp. 1307-1325	3
		The prolongation of the survival times of mice implanted with TLX5 cells by treatment with methotrexate encapsulated in erythrocytes, Alpar, H.O., Lewis, D.A.	Biochemical Pharmacology		1987	36 (18), pp. 3081-3083	2
		Drug-delivery by ion-exchange: Part III: Interaction of ester pro-drugs of propranolol with cationic exchange resins, Irwin, W.J., Belaid, K.A., Alpar,	Drug Development and Industrial Pharmacy		1987	13 (9-11), pp. 2047-2066	3

	H.O.					
	Formulation studies on [2-amino-5-bromo-phenyl-4(3)-pyrimidinone] (ABPP), an interferon inducer. Anti-cancerogenic agent, Alpar, H.O., Whitmash, S.J., Ismail, H., (...), Belaid, K.A., Stevens, M.F.G.	Drug Development and Industrial Pharmacy		1986	12 (11-13), pp. 1795-1811	5
	Therapeutic efficacy of asparaginase encapsulated in intact erythrocytes, Alpar, H.O., Lewis, D.A.	Biochemical Pharmacology		1985	34 (2), pp. 257-261	2
	The in vitro incorporation and release of hydroxocobalamin by liposomes, Alpar, O.H., Bamford, J.B., Walters, V.	International Journal of Pharmaceutics		1981	7 (4), pp. 349-351	3
	Sustained-release characteristics of tablets of ethylcellulose microcapsules containing potassium phenethicillin, Alpar, O.H.	Farmaco, Edizione Pratica		1981	36 (8), pp. 366-373	1
	Effect of suspending agents on the bioavailability of suspensions of sulphathiazole, Alpar, H.O., Hersey, J.A.	Farmaco, Edizione Pratica		1979	34 (12), pp. 532-541	2
	The compression properties of lactose. Alpar, O., Hersey, J.A., Shotton, E.	Journal of Pharmacy and Pharmacology		1970	pp. Suppl:1S-7S	3
	The possible use of polytetrafluoroethylene (Fluon) as a tablet lubricant. Alpar, O., Deer, J.J., Hersey, J.A., Shotton, E.	Journal of Pharmacy and Pharmacology		1969	21, pp. Suppl:6S-8S	4
<b>7.7. Diğer yayınlar</b>	Alpar, H.O., Özsoy, Y., Cevher, E., Nanotaşıyıcılarla Aşı Uygulaması/ Nanofarmasötikler ve Uygulamaları (Editör: Ayla Zırh-Gürsoy), Aktif Matbaa ve Reklam Hizm. San. Tic. Ltd. Şti.,		İstanbul	2014	277-290	3
	Alpar, H.O., Cevher, E., Özsoy, Y., "Gen Taşıyıcı Sistemler", Nanofarmasötikler ve Uygulamaları (Editör:	Kontrollü Salım Sistemleri Derneği	İstanbul	2014	261-275	3

		Ayla Zırh-Gürsoy), Yayın No.3, Aktif Matbaa ve Reklam Hizm. San. Tic. Ltd. Şti.,					
	<b>7.8. Akademik Çeviriler</b>						
	<b>7.9. Yazılan Ulusal Kitaplar</b>						
	<b>7.10. Yazılan Uluslararası Kitaplar</b>	Xiongwei Li, Masaki Uchida, H. Oya Alpar, and Peter Mertens., “Biolistic Transfection of Human Embryonic Kidney (HEK) 293 Cells” Biolistic DNA Delivery (Eds. Stephan,Sudowe, Angelika B. Reske- Kunz)	Humana Press		2012		4
	<b>7.11. Yazılan Ulusal Kitaplarda Bölümler</b>						
	<b>7.12. Yazılan Uluslararası Kitaplarda Bölümler</b>	H. Oya Alpar, Vincent W. Bramwell, Eva Veronesi, Karin E. Darpel, Paul-Pierre Pastoret, Peter P.C. Mertens, “ Bluetongue virus vaccines past and present ”	Bluetongue		2009	bölüm 18, pages 397-428	8
		H.O. Alpar and M.J. Groves, “VACCINES: ANCIENT MEDICINES TO MODERN THERAPEUTICS”, Pharmaceutical Biotechnology Second Edition, CRC Press Editor(s): Michael J. Groves			2005	bölüm 11	2
		H.O. Alpar and W.J. .Irwin, “Some Unique Applications of Erythrocytes as Carrier Systems” Red Blood Cells as Carriers for Drugs: Potential Therapeutic Applications - International Meeting Proceedings, Edited by C.etc. Ropars, Edited by M. Chassaigne, Edited by C. Nicolau				1987	sayfalar 1- 10

<b>8. Projeler</b>	1.	Expression and formulation of Bluetongue virus genes and proteins for development of effective vaccination strategies
	2.	Exploring the enhancement of immune responses of the killed bacteria <i>M.vaccae</i> delivered orally.
	3.	Proof of concept studies: The tissue distribution of SiRNA following respiratory application.
	4.	Development of micro-nano particulate delivery systems for vaccines using SCF technology
	5.	Site-specific delivery of Biodefense antibodies
	6.	Development of novel particles for pulmonary delivery of antigen and gene vaccine delivery
	7.	Exploring biocomposite membrane incorporating microparticles as scaffolds and carriers for corneal transplantation of stem cells
	8.	Setting up Supercritical fluid technology for producing scalable/ solvent free particulate vaccine carriers
	9.	Scaleable continuous homogeniser to produce nanosized biopharmaceutical formulations
	10.	Development of a safe, efficacious BTV vaccination strategy for Europe
	11.	Single dose vaccine delivery using microparticulate carriers
	12.	Effect of freeze-drying on bioactive DNA/RNA delivery systems
	13.	Formulation of lipid enveloped gene vectors and vaccines
	14.	Formulation of novel particulate Metered Dose Inhaler preparations for effective pulmonary delivery of proteins
	15.	A mechanistic study of the fundamental aspects of mucosal immunization: Development of in vitro techniques and in vitro-in vivo correlations
	16.	Formulation of particulate delivery systems using supercritical fluids

	<b>Görevi</b>	<b>Yeri</b>	<b>Tarihi</b>
<b>9. İdari Görevler</b>	Galenik Farmasi( Farmasötik Teknoloji) Anabilim Dalı Başkanı	Hacettepe Üniversitesi, Ankara	(1971-1975)
	Galenik Farmasi(Farmasötik Teknoloji), Endüstriyel ve Klinik Eczacılık Anabilim Dalı Başkan	Hacettepe Üniversitesi, Ankara	(1975-1981)
	Farmasötik ve Biyolojik Bilimler Bölümü Kıdemli Araştırma Görevlisi	Aston Üniversitesi	(1982-1989)
	Kıdemli Öğretim Görevlisi / Öğretim Görevlisi, Farmasötik ve Biyolojik Bilimler Bölümü	Aston Üniversitesi	(1990-1999)
	Okuyucu, Farmasötik ve Biyolojik Bilimler Bölümü	Aston Üniversitesi	(2000-2001)
	Profesör, İlaç Teslimi Araştırma Grubu Merkezi Başkanı, Eczacılık Fakültesi	Londra Üniversitesi	(Mayıs 2001-2009)
	Eczacılık Fakültesi, Farmasötik Teknoloji Anabilim Dalı Kurucu Profesörü	Altınbaş Üniversitesi	2012
	Eczacılık Teknolojisi Bölümü Başkanı	Altınbaş Üniversitesi	2012 - günümüz
	Farmasötik Biyoteknoloji Anabilim Dalı Başkanı	Altınbaş Üniversitesi	2012 - günümüz

	<b>Kuruluşun Adı</b>	<b>Akademisyenin Görevi</b>	<b>Tarihi</b>
<b>10. Bilimsel ve Mesleki</b>	<b>10.1. Uluslararası Akademik ve Araştırma Kuruluşlarına Üyelikler</b>	DSÖ'nün Yeni Aşı Sunum Sistemleri Yönlendirme Komitesi	Geçici Danışmanı
		Kontrollü Salım Derneği	
		İngiliz İmmünoloji Derneği	
		Uluslararası Eczacılık Federasyonu, FIP	

<b>Kuruluşlara Üyelikler</b>		Kontrollü Salm Sistemleri Derneği		
	<b>10.2. Ziyaretçi Öğretim Üyelikleri</b>			
	<b>10.3. Hakemlikler</b>	Vaccine	Hakemlik	
		Infection and Immunity	Hakemlik	
		Journal of Pharmaceutical Sciences	Hakemlik	
		Pharmaceutical Research	Hakemlik	
		Journal of Lipid Research	Hakemlik	
		The FABAD Journal of Pharmaceutical Sciences	Hakemlik	
		Journal of Drug Delivery Science and Technology	Hakemlik	
		Journal of Drug Targeting	Hakemlik	
		Journal of Controlled Release	Hakemlik	
		International Journal of Pharmaceutics	Hakemlik	
		Pharmaceutical Development and Technology	Hakemlik	
		Journal of Pharmacology and Experimental Therapeutics	Hakemlik	
		Nanomedicine	Hakemlik	
Advanced Drug Delivery Research	Hakemlik			
Journal of Pharmacy and Pharmacology	Hakemlik			

<b>11. Burslar ve Ödüller</b>	<b>Burs / Ödül / Program Adı</b>	<b>Tarihi</b>
	TÜBİTAK 50.yıl Özel Ödülü – Türkiye Cumhurbaşkanı tarafından takdim edilmiştir	2015
	British Council One Year Study Award for a PhD student	2005
	Best Poster Award - DNA delivery, Biyomed, İstanbul	1996
	British Council Fellowship	1979-1980
	Turkish Government / British Council Scholarship for PhD Studies in London	1968-1971

<b>12. Son 2 yılda verilen dersler</b>	<b>Akademik Yıl</b>	<b>Dönem</b>	<b>Dersin Adı</b>	<b>Yüksek Lisans / Doktora Dersi</b>
	<b>2018-2019</b>	<b>Güz</b>	Farmasötik Teknoloji I	Biyofarmasötikler
			Gıda ve sağlık	Biyolojik Bariyerlerin Aşılması

			Mezuniyet Projesi I	Klinik farmasötikler
		<b>Bahar</b>	Farmasötik Teknoloji II	Nano İlaçlar ve Hedeflenmiş İlaç Taşıyıcı Sistemler
			Modern İlaçların Formülasyonunda Karşılaşılan Zorluklar: Biyofarmasötikler/Biyolojikler	
			Kozmetoloji	
			Mezuniyet Projesi II	
	<b>2019-2020</b>	<b>Güz</b>	Farmasötik Teknoloji I	Biyofarmasötikler
			Farmasötik Bioteknoloji	Biyolojik Bariyerlerin Aşılması
			Gıda ve sağlık	Klinik farmasötikler
			Mezuniyet Projesi I	
		<b>Bahar</b>	Mezuniyet Projesi II	